231 related articles for article (PubMed ID: 33915460)
1. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.
Sun LY; Chen C; Su J; Li JQ; Jiang Z; Gao H; Chigan JZ; Ding HH; Zhai L; Yang KW
Bioorg Chem; 2021 Jul; 112():104889. PubMed ID: 33915460
[TBL] [Abstract][Full Text] [Related]
2. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
[TBL] [Abstract][Full Text] [Related]
3. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
[TBL] [Abstract][Full Text] [Related]
4. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
Parise A; Romeo I; Russo N; Marino T
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
[TBL] [Abstract][Full Text] [Related]
5. Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of M
Mangiavacchi F; Botwina P; Menichetti E; Bagnoli L; Rosati O; Marini F; Fonseca SF; Abenante L; Alves D; Dabrowska A; Kula-Pacurar A; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Rizzuti B; Abian O; Lenardão EJ; Velazquez-Campoy A; Pyrc K; Sancineto L; Santi C
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208928
[TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
Sies H; Parnham MJ
Free Radic Biol Med; 2020 Aug; 156():107-112. PubMed ID: 32598985
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.
Thun-Hohenstein STD; Suits TF; Malla TR; Tumber A; Brewitz L; Choudhry H; Salah E; Schofield CJ
ChemMedChem; 2022 Feb; 17(4):e202100582. PubMed ID: 34850566
[TBL] [Abstract][Full Text] [Related]
8. Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.
Cui J; Jia J
Eur J Med Chem; 2021 Dec; 225():113789. PubMed ID: 34438124
[TBL] [Abstract][Full Text] [Related]
9. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
[TBL] [Abstract][Full Text] [Related]
10. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Menéndez CA; Byléhn F; Perez-Lemus GR; Alvarado W; de Pablo JJ
Sci Adv; 2020 Sep; 6(37):. PubMed ID: 32917717
[TBL] [Abstract][Full Text] [Related]
12. Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals.
Xu YS; Chigan JZ; Li JQ; Ding HH; Sun LY; Liu L; Hu Z; Yang KW
Bioorg Chem; 2022 Jul; 124():105799. PubMed ID: 35462235
[TBL] [Abstract][Full Text] [Related]
13. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
Awoonor-Williams E; Abu-Saleh AAA
Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
[TBL] [Abstract][Full Text] [Related]
14. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
Zmudzinski M; Rut W; Olech K; Granda J; Giurg M; Burda-Grabowska M; Kaleta R; Zgarbova M; Kasprzyk R; Zhang L; Sun X; Lv Z; Nayak D; Kesik-Brodacka M; Olsen SK; Weber J; Hilgenfeld R; Jemielity J; Drag M
Sci Rep; 2023 Jun; 13(1):9161. PubMed ID: 37280236
[TBL] [Abstract][Full Text] [Related]
15. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2.
Rieder GS; Nogara PA; Omage FB; Duarte T; Dalla Corte CL; da Rocha JBT
Comput Biol Chem; 2023 Dec; 107():107956. PubMed ID: 37748316
[TBL] [Abstract][Full Text] [Related]
16. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
Amporndanai K; Meng X; Shang W; Jin Z; Rogers M; Zhao Y; Rao Z; Liu ZJ; Yang H; Zhang L; O'Neill PM; Samar Hasnain S
Nat Commun; 2021 May; 12(1):3061. PubMed ID: 34031399
[TBL] [Abstract][Full Text] [Related]
17. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
[TBL] [Abstract][Full Text] [Related]
18. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.
Di Micco S; Musella S; Sala M; Scala MC; Andrei G; Snoeck R; Bifulco G; Campiglia P; Fasano A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502335
[TBL] [Abstract][Full Text] [Related]
19. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
Hicks EG; Kandel SE; Lampe JN
Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
[TBL] [Abstract][Full Text] [Related]
20. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M
Ibrahim MAA; Abdelrahman AHM; Mohamed TA; Atia MAM; Al-Hammady MAM; Abdeljawaad KAA; Elkady EM; Moustafa MF; Alrumaihi F; Allemailem KS; El-Seedi HR; Paré PW; Efferth T; Hegazy MF
Molecules; 2021 Apr; 26(7):. PubMed ID: 33916461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
